TY - JOUR
T1 - Low-dose hydrocortisone for treatment of chronic fatigue syndrome
T2 - A randomized controlled trial
AU - McKenzie, Robin
AU - O'Fallon, Ann
AU - Dale, Janet
AU - Demitrack, Mark
AU - Sharma, Geetika
AU - Deloria, Maria
AU - Garcia-Borreguero, Diego
AU - Blackwelder, William
AU - Straus, Stephen E.
N1 - Copyright:
Copyright 2007 Elsevier B.V., All rights reserved.
PY - 1998/9/23
Y1 - 1998/9/23
N2 - Context. - Chronic fatigue syndrome (CFS) is associated with a dysregulated hypothalamic-pituitary adrenal axis and hypocortisolemia. Objective. - To evaluate the efficacy and safety of low-dose oral hydrocortisone as a treatment for CFS. Design. - A randomized, placebo- controlled, double-blind therapeutic trial, conducted between 1992 and 1996. Setting. - A single-center study in a tertiary care research institution. Patients. - A total of 56 women and 14 men aged 18 to 55 years who met the 1988 Centers for Disease Control and Prevention case criteria for CFS and who withheld concomitant treatment with other medications. Intervention. - Oral hydrocortisone, 13 mg/m2 of body surface area every morning and 3 mg/m2 every afternoon, or placebo, for approximately 12 weeks. Main Outcome Measures. - A global Wellness scale and other self-rating instruments were completed repeatedly before and during treatment. Resting and cosyntropin- stimulated cortisol levels were obtained before and at the end of treatment. Patients recorded adverse effects on a checklist. Results. - The number of patients showing improvement on the Wellness scale was 19 (54.3%) of 35 placebo recipients vs 20 (66.7%) of 30 hydrocortisone recipients (P=.31). Hydrocortisone recipients had a greater improvement in mean Wellness score (6.3 vs 1.7 points; P= .06), a greater percentage (53% vs 29%; P= .04) recording an improvement of 5 or more points in Wellness score, and a higher average improvement in Wellness score on more days than did placebo recipients (P<.001). Statistical evidence of improvement was not seen with other self-rating scales. Although adverse symptoms reported by patients taking hydrocortisone were mild, suppression of adrenal glucocorticoid responsiveness was documented in 12 patients who received it vs none in the placebo group (P<.001). Conclusions. - Although hydrocortisone treatment was associated with some improvement in symptoms of CFS, the degree of adrenal suppression precludes its practical use for CFS.
AB - Context. - Chronic fatigue syndrome (CFS) is associated with a dysregulated hypothalamic-pituitary adrenal axis and hypocortisolemia. Objective. - To evaluate the efficacy and safety of low-dose oral hydrocortisone as a treatment for CFS. Design. - A randomized, placebo- controlled, double-blind therapeutic trial, conducted between 1992 and 1996. Setting. - A single-center study in a tertiary care research institution. Patients. - A total of 56 women and 14 men aged 18 to 55 years who met the 1988 Centers for Disease Control and Prevention case criteria for CFS and who withheld concomitant treatment with other medications. Intervention. - Oral hydrocortisone, 13 mg/m2 of body surface area every morning and 3 mg/m2 every afternoon, or placebo, for approximately 12 weeks. Main Outcome Measures. - A global Wellness scale and other self-rating instruments were completed repeatedly before and during treatment. Resting and cosyntropin- stimulated cortisol levels were obtained before and at the end of treatment. Patients recorded adverse effects on a checklist. Results. - The number of patients showing improvement on the Wellness scale was 19 (54.3%) of 35 placebo recipients vs 20 (66.7%) of 30 hydrocortisone recipients (P=.31). Hydrocortisone recipients had a greater improvement in mean Wellness score (6.3 vs 1.7 points; P= .06), a greater percentage (53% vs 29%; P= .04) recording an improvement of 5 or more points in Wellness score, and a higher average improvement in Wellness score on more days than did placebo recipients (P<.001). Statistical evidence of improvement was not seen with other self-rating scales. Although adverse symptoms reported by patients taking hydrocortisone were mild, suppression of adrenal glucocorticoid responsiveness was documented in 12 patients who received it vs none in the placebo group (P<.001). Conclusions. - Although hydrocortisone treatment was associated with some improvement in symptoms of CFS, the degree of adrenal suppression precludes its practical use for CFS.
UR - http://www.scopus.com/inward/record.url?scp=0032581975&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032581975&partnerID=8YFLogxK
U2 - 10.1001/jama.280.12.1061
DO - 10.1001/jama.280.12.1061
M3 - Article
C2 - 9757853
AN - SCOPUS:0032581975
SN - 0098-7484
VL - 280
SP - 1061
EP - 1066
JO - JAMA
JF - JAMA
IS - 12
ER -